Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once dai...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Rheum Dis
Main Authors: Keystone, Edward C, Taylor, Peter C, Tanaka, Yoshiya, Gaich, Carol, DeLozier, Amy M, Dudek, Anna, Zamora, Jorge Velasco, Cobos, Jose Arturo Covarrubias, Rooney, Terence, de Bono, Stephanie, Arora, Vipin, Linetzky, Bruno, Weinblatt, Michael E
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2017
Fag:
Clinical and Epidemiological Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705852/
https://ncbi.nlm.nih.gov/pubmed/28798049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211259
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker